High-yielding investments can be enticing, but that doesn't mean that they're safe.Income-seeking investors often invest in exchange-traded funds (ETFs) as a good way to diversify and collect a dividend. However, if the dividend yield is exceptionally high, is it too good to true? While diversifying via ETFs provides investors with some added safety, it's still important to take a close look at the types of stocks within a fund before investing in it and relying on its payout.One high-yielding ETF that may ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PubMatic, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from February 27, 2025, to August 11, 2025, and the lead plaintiff deadline is October 20, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that PubMatic made false and misleading statements regarding its business operations, particularly concerning a top demand side platform (DSP) buyer shifting clients to a new platform [4]. - This shift resulted in a reduction of ad spend and revenue for PubMatic, contradicting the positive statements made by the defendants [4]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information [4].

Core Insights - Digi Power X Inc reported strong financial results for August, with revenues of $3.5 million from Bitcoin mining and energy trading, and a cash balance exceeding $29 million [1][5][6] - The company is valued at over $100 million with an annualized run rate exceeding $40 million, indicating strong growth momentum [2][6] - The ongoing conversion of the Alabama facility into a tier three AI data center is progressing well, with expectations to announce a tenant by the end of the year [7][9] Financial Performance - Revenues for August reached $3.5 million, driven by Bitcoin mining and energy trading activities [1][5] - The company holds a cash balance of over $29 million, which includes US dollars, Bitcoin, and Ethereum [1][5] - Ethereum holdings have increased significantly, with over 1,000 ether acquired, reflecting a 93% month-over-month growth [5][6] Strategic Developments - The Alabama facility is being converted into a tier three AI data center, with a power capacity of 40MW and total power availability of 55MW [8] - The company is collaborating with Super Micro to implement AI-ready modular solution pods that can scale from half a megawatt to the full capacity of the site [8] - Discussions are ongoing with major institutions for project financing, anticipated to be on favorable terms [9] Market Position - There is increasing institutional interest in Digi Power X, with new research coverage initiated by Alliance Global Partners [10][11] - The company is experiencing heightened demand in the cryptocurrency space, which is described as "white hot" [11] - The focus remains on executing the development of the Alabama facility and securing tenants [11]

Nvidia expects artificial intelligence spending to increase at an impressive rate over the next few years.Nvidia (NVDA -2.78%) CEO and co-founder Jensen Huang made some jaw-dropping claims during the company's Q2 earnings call. Chief among them was the projection that a $3 trillion to $4 trillion artificial intelligence (AI) infrastructure opportunity will emerge by 2030. Considering the top four AI hyperscalers are spending about $600 billion annually, according to Huang, that's a massive increase for the ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Fortinet, Inc. and its officers or directors following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - On August 6, 2025, Fortinet reported disappointing second quarter 2025 financial results, leading to confusion among investors regarding the company's performance [3]. - The company indicated that 40% to 50% of its accelerated firewall refresh, estimated at a $450 million opportunity, was completed, yet product revenue growth and billings did not meet expectations [3]. - Following the announcement, Fortinet's stock price fell by $21.28 per share, or 22.03%, closing at $75.30 per share on August 7, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Fortinet investors, suggesting potential securities fraud or other unlawful practices by the company and its leadership [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Bumble Inc. and its officers or directors, following a significant drop in the company's paying users and a subsequent decline in stock price [1][3][4]. Group 1: Company Performance - Bumble reported a 8.7% decrease in total paying users, dropping to 3.8 million in Q2 2025, compared to 4 million in Q1 2025 and 4.2 million in Q4 2024 [3]. - The company has introduced new AI-powered features aimed at enhancing trust and safety, but analysts suggest these measures may negatively impact user and payer growth in the short term due to stricter verification processes [3]. Group 2: Market Reaction - Following the release of its Q2 results, Bumble's stock price fell by $1.22, or 15.94%, closing at $6.43 per share on August 7, 2025 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and failed to account for rising customer acquisition costs, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of James Hardie Industries plc regarding potential securities fraud or unlawful business practices by the company and its officers [1] - James Hardie reported a 29% decline in first-quarter profit for the period ending June 30, 2025, and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [3] - Following the announcement of its financial results, James Hardie's ADR price fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [3] Company Overview - James Hardie Industries plc is facing scrutiny from investors and legal investigations related to possible securities fraud [1] - The company has experienced significant financial challenges, as indicated by the substantial decline in profit and negative earnings projections [3] Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of advocating for victims of securities fraud [4]

Core Viewpoint - Zai Lab Limited is under investigation for potential securities fraud following the release of disappointing final results from a Phase 3 clinical trial for its drug bemarituzumab, leading to a significant drop in its stock price [1][3]. Group 1: Company Overview - Zai Lab Limited is a biopharmaceutical company listed on NASDAQ under the ticker ZLAB [1]. - The company is currently facing claims of securities fraud or unlawful business practices, prompting an investigation by Pomerantz LLP [1]. Group 2: Clinical Trial Results - On September 3, 2025, Zai Lab announced the completion of the final analysis of the Phase 3 FORTITUDE-101 trial for bemarituzumab in combination with chemotherapy for first-line gastric cancer [3]. - The interim analysis had shown a significant improvement in overall survival compared to chemotherapy alone, but the final analysis indicated that this survival advantage had diminished [3]. - Zai Lab plans to await results from the FORTITUDE-102 trial before proceeding with regulatory filing, with data readout expected by the end of 2025 or the first half of 2026 [3]. Group 3: Market Reaction - Following the announcement of the final trial results, Zai Lab's American Depositary Receipt (ADR) price fell by $2.04, or 6.12%, closing at $31.30 per ADR on September 3, 2025 [3].

Core Viewpoint - A class action lawsuit has been filed against Tronox Holdings Plc for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Tronox and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 3, 2025, to request to be appointed as Lead Plaintiff if they purchased Tronox securities during the Class Period [2]. Group 2: Financial Performance - On July 30, 2025, Tronox reported a significant reduction in sales of its TiO2 products, attributing the decline to a softer coatings season and heightened competition [4]. - Following the announcement, Tronox revised its 2025 financial outlook, lowering its full-year revenue guidance and reducing its dividend by 60% [4]. - As a result of the negative news, Tronox's stock price fell by $1.95 per share, or 37.94%, closing at $3.19 per share on July 31, 2025 [5].